Hemlibra 105mg Injection

About

Hemlibra 105mg Injection contains emicizumab, a bispecific factor IXa- and factor X-directed antibody. It is designed to bridge activated factor IX and factor X, thereby restoring the function of missing activated factor VIII, which is essential for effective blood coagulation. This medication is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

Emicizumab provides a novel therapeutic approach for hemophilia A, offering subcutaneous administration and a prolonged half-life, which allows for less frequent dosing compared to traditional factor VIII replacement therapies. Its mechanism of action bypasses the need for factor VIII, making it effective even in patients who have developed inhibitors against factor VIII.

Uses

• Routine prophylaxis for hemophilia A
• Prevention of bleeding episodes in hemophilia A
• Management of hemophilia A with factor VIII inhibitors
• Management of hemophilia A without factor VIII inhibitors

Directions For Use

Administer subcutaneously as directed by a healthcare professional. Follow the prescribed dosing schedule carefully.

Benefits

• Significantly reduces bleeding frequency
• Improves quality of life for patients
• Subcutaneous administration for convenience
• Effective in patients with factor VIII inhibitors
• Long-acting, allowing less frequent dosing
• Reduces the need for frequent intravenous infusions

Side Effects

• Injection site reactions (pain, redness, swelling)
• Headache
• Arthralgia (joint pain)
• Fever
• Diarrhea
• Rash
• Myalgia (muscle pain)
• Nausea
• Vomiting
• Fatigue
• Hypersensitivity reactions (rare)
• Thrombotic microangiopathy (very rare)

Safety Measures

• Alcohol - No direct interaction, but excessive alcohol consumption can impair coagulation and overall health.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus; consult a physician.
• Breastfeeding - Unknown if excreted in human milk; caution advised, consult a physician before use.
• Liver - No specific dose adjustment needed for mild to moderate hepatic impairment; use with caution in severe impairment.
• Kidney - No specific dose adjustment needed for mild to moderate renal impairment; use with caution in severe impairment.
• Lung - No specific lung concerns, but monitor for any signs of thrombotic events, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.